Summarized by Masters of Longevity from Longevity Technology.
A proteomic panel separated ALS patients from healthy controls with high accuracy.
Key Takeaways
- A ten‑protein plasma signature identified ALS with 98.3% accuracy.
- The panel showed AUC 0.992, outperforming neurofilament light chain.
- Findings are preliminary and require larger, diverse validation cohorts.
